Market news
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing oncology. Read why STTK stock is a buy.
Two analysts weighed in with new takes on the biotech.
Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analyst
The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
An analyst initiated coverage of the biotech with a buy recommendation.
Wall Street analysts changed outlook on top names. For full changes, upgrades, downgrades and initiations, see analyst ratings page.
This is the newest page. Registered accounts read further back.